Antioxidants 2014, 3(2), 245-277; doi:10.3390/antiox3020245

Melatonin Therapy in Patients with Alzheimer’s Disease

1,* email, 1email, 2email, 2email and 2email
Received: 8 February 2014; in revised form: 9 March 2014 / Accepted: 17 March 2014 / Published: 10 April 2014
(This article belongs to the Special Issue Oxidative Stress and Neurodegenerative Diseases)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Alzheimer’s disease (AD) is a major health problem and a growing recognition exists that efforts to prevent it must be undertaken by both governmental and non-governmental organizations. In this context, the pineal product, melatonin, has a promising significance because of its chronobiotic/cytoprotective properties potentially useful for a number of aspects of AD. One of the features of advancing age is the gradual decrease in circulating melatonin levels. A limited number of therapeutic trials have indicated that melatonin has a therapeutic value as a neuroprotective drug in the treatment of AD and minimal cognitive impairment (which may evolve to AD). Both in vitro and in vivo, melatonin prevented the neurodegeneration seen in experimental models of AD. For these effects to occur, doses of melatonin about two orders of magnitude higher than those required to affect sleep and circadian rhythmicity are needed. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects, which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50–100 mg/day are urgently needed to assess its therapeutic validity in neurodegenerative disorders such as AD.
Keywords: melatonin; Alzheimer’s disease; neurodegeneration; free radicals; oxidative stress; aging; mild cognitive impairment; melatonin analogs
PDF Full-text Download PDF Full-Text [564 KB, uploaded 10 April 2014 09:18 CEST]

Export to BibTeX |

MDPI and ACS Style

Cardinali, D.P.; Vigo, D.E.; Olivar, N.; Vidal, M.F.; Brusco, L.I. Melatonin Therapy in Patients with Alzheimer’s Disease. Antioxidants 2014, 3, 245-277.

AMA Style

Cardinali DP, Vigo DE, Olivar N, Vidal MF, Brusco LI. Melatonin Therapy in Patients with Alzheimer’s Disease. Antioxidants. 2014; 3(2):245-277.

Chicago/Turabian Style

Cardinali, Daniel P.; Vigo, Daniel E.; Olivar, Natividad; Vidal, María F.; Brusco, Luis I. 2014. "Melatonin Therapy in Patients with Alzheimer’s Disease." Antioxidants 3, no. 2: 245-277.

Antioxidants EISSN 2076-3921 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert